Compare Davita Inc (DVA) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Sezzle Inc — how do they compare? Davita Inc trades at $179.07 (market cap $11.29B), while Sezzle Inc trades at $126 (market cap $3.95B). The key difference: Davita Inc is far larger — about 2.9× Sezzle Inc's market cap, and Davita Inc is more actively traded (582,204 versus 550,075). Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Sezzle Inc for 15 Days on average.
| DVA | SEZL | |
|---|---|---|
Market Cap | $11.29B | $3.95B |
Volume | 582,204 | 550,075 |
Sector | Health | Financials |
52-Week High | $240.96 | $188.55 |
52-Week Low | $103.87 | $50.97 |
Typical Hold Time | 113 Days | 15 Days |
Enterprise Value | $24.01B | $3.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.02, up 1.26% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 6.05% net margins and 635% ROE. Recent partnerships with Humana expand value-based kidney care services, while institutional investors like BlackRock added significant positions. Revenue growth remains steady at $13.6B annually with improving profitability trends.
DVA presents a mixed outlook with strong operational performance offset by technical weakness. The 43% upside to consensus price target of $235.67 offers potential, but high debt levels and regulatory risks require monitoring. Recent earnings momentum and expanding Medicare partnerships support long-term growth, though current technical indicators suggest near-term consolidation.
Sezzle (SEZL) surged 9.98% to $125.21, reflecting strong momentum after consistently beating earnings estimates. The stock shows bullish technical signals with robust fundamentals including 51.7% revenue growth in Q2 2026 and exceptional profitability metrics (ROE 88.85%, net margin 30.35%). Recent product launches like Sezzle Send and SezzleCash are driving user growth and platform engagement.
Outlook remains positive with 35% revenue growth guidance and 35.9% upside to consensus price target of $168. Key risks include BNPL competition and potential credit quality concerns, but strong institutional buying and analyst optimism support the bullish case for continued growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
